Datopotamab deruxtecan: A novel antibody drug conjugate for triple-negative breast cancer
Triple negative breast cancer (TNBC) represents the breast cancer subtype with least favorable outcome because of the lack of effective treatment options and its molecular features. Recently, ADCs have dramatically changed the breast cancer treatment landscape; the anti-TROP2 ADC Sacituzumab Govitec...
Main Authors: | Francesca Matilde Schipilliti, Denise Drittone, Federica Mazzuca, Daniele La Forgia, Deniz Can Guven, Alessandro Rizzo |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-04-01
|
Series: | Heliyon |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844024044165 |
Similar Items
-
Safety evaluation of Datopotamab deruxtecan for triple-negative breast cancer: a meta-analysis
by: Gennaro Gadaleta-Caldarola, et al.
Published: (2023-01-01) -
Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer
by: Mythili Shastry, et al.
Published: (2022-12-01) -
HER2-/HER3-Targeting Antibody—Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors
by: Kimio Yonesaka
Published: (2021-03-01) -
Advances in the study of marketed antibody-drug Conjugates (ADCs) for the treatment of breast cancer
by: Yan Liang, et al.
Published: (2024-01-01) -
Real-World Data of Trastuzumab Deruxtecan for Advanced Gastric Cancer: A Multi-Institutional Retrospective Study
by: Toshihiko Matsumoto, et al.
Published: (2022-04-01)